Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 41, n° 6
pages 1002-1007 (décembre 1999)
Doi : 10.1016/S0190-9622(99)70261-6
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
 

Karl R. Beutner, MD, PhDa,b,c, John K. Geisse, MDa,b,c, Donita Helman, BSNc, Terry L. Fox, MSd, Angela Ginkeld, Mary L. Owens, MDd
San Francisco and Vallejo, California, and St Paul, Minnesota 
From the Department of Dermatology, University of California, San Francisco,a the Department of Medicine, Sutter Solano Medical Center, Vallejo,b Solano Dermatology Associates, Vallejo,c and 3M Pharmaceuticals, St Paul.d 

Abstract

Background: Basal cell carcinoma (BCC) responds to interferon therapy. Imiquimod is a cytokine and interferon inducer. Objective: This randomized, double-blind pilot trial evaluated the safety and efficacy of imiquimod 5% cream versus vehicle in the treatment of BCC. Methods: In this population of 35 patients with BCC, 24 received imiquimod 5% cream and 11 received vehicle cream in 1 of 5 dosing regimens for up to 16 weeks. Six weeks after treatment, an excisional biopsy of the target site was performed. Results: BCC cleared (on the basis of histologic examination) in all 15 patients (100%) dosed twice daily, once daily, and 3 times weekly; in 3 of 5 (60%) patients dosed twice weekly; 2 of 4 (50%) dosed once weekly; and in 1 of 11 (9%) treated with vehicle. Adverse events were predominantly local reactions at the target tumor site, with the incidence and severity of local skin reactions declining in groups dosed less frequently. Conclusion: Imiquimod 5% cream shows clinical efficacy in the treatment of BCC. (J Am Acad Dermatol 1999;41:1002-7.)

The full text of this article is available in PDF format.

 Supported by a grant from 3M Pharmaceuticals, St Paul, Minnesota.
 Reprint requests: Karl Beutner, MD, PhD, Solano Dermatology Associates, 127 Hospital Dr, Ste 204, Vallejo, CA 94589.
 0190-9622/99/$8.00 + 0  16/1/101291



© 1999  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@